NCT02435173View on ClinicalTrials.gov

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 24, 2015

Primary Completion Date

August 16, 2021

Study Completion Date

August 16, 2021

Conditions
Common Variable Immunodeficiency (CVID), APDS / PASLI
Interventions
DRUG

CDZ173

CDZ173 10 and 70 mg capsules for oral administration.

OTHER

Placebo

Placebo capsules for oral administration

Trial Locations (10)

20814

National Institute of Health NIH, Bethesda

25123

Novartis Investigative Site, Brescia

90127

Novartis Investigative Site, Palermo

117198

Novartis Investigative Site, Moscow

223053

Novartis Investigative Site, Minsk

150 00

Novartis Investigative Site, Prague

01307

Novartis Investigative Site, Dresden

Unknown

Novartis Investigative Site, Dublin

3000 CA

Novartis Investigative Site, Rotterdam

BT9 7AB

Novartis Investigative Site, Belfast

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY